The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| NeoGenomics Inc. | COM NEW | 64049M209 | 144,424 | 4,661,835 | SH | SOLE | 4,661,835 | 0 | 0 | ||
| Horizon Therapeutics Public Limited Company | SHS | G46188101 | 17,581 | 316,325 | SH | SOLE | 316,325 | 0 | 0 | ||
| Vericel Corporation | COM | 92346J108 | 14,955 | 1,082,155 | SH | SOLE | 1,082,155 | 0 | 0 | ||
| Five9, Inc. | COM | 338307101 | 7,082 | 63,995 | SH | SOLE | 63,995 | 0 | 0 | ||
| Intersect ENT Inc. | COM | 46071F103 | 1,051 | 77,630 | SH | SOLE | 77,630 | 0 | 0 | ||